Key Takeaways
- • Three major global PE firms—Bain Capital, EQT, and TPG—have submitted non-binding bids to acquire a controlling equity stake in UK-based nutraceutical company Vitabiotics, according to sources familiar with the transaction.
- • The transaction is valued at approximately $1.2 billion, positioning this as a significant mid-market buyout in the consumer health and wellness sector.
- • Vitabiotics, founded in 1971 and controlled by the Indian-origin Lalwani family, generates revenue from flagship brands including Wellman, Wellwoman, and Hairfollic, with additional distribution through its Indian subsidiary Meyer Organics.
- • The three PE bidders have advanced to the final round of discussions, indicating the sale process is in an advanced stage with formal offers now on the table.
- • Vitabiotics is led by CEO Tej Lalwani (son of founder Kartar Lalwani), suggesting potential founder involvement in the transaction structure.
Summary
Three of the world's largest private equity firms—Bain Capital, EQT, and TPG—are competing to acquire a controlling stake in Vitabiotics Ltd., a UK-based nutraceutical and wellness products company. The three bidders have submitted non-binding offers in what appears to be the final competitive round of a structured sale process, according to sources familiar with the matter.
The transaction is expected to value Vitabiotics at approximately $1.2 billion. The company operates as a leading player in the global vitamins and dietary supplements market, with established brand recognition across multiple product lines. Its primary offerings include Wellman and Wellwoman supplement brands, alongside Hairfollic, a hair health product. The company also maintains a significant presence in the Indian market through Meyer Organics, its domestic subsidiary, expanding its geographic footprint beyond its UK headquarters.
Vitabiotics was founded in 1971 by Kartar Lalwani and remains controlled by the Lalwani family. The company is currently led by Chief Executive Officer Tej Lalwani, the founder's son, who oversees day-to-day operations. The Lalwani family's involvement as controlling shareholders suggests they remain central to the transaction—whether as sellers, partial roll-over equity holders, or both.
The competitive bidding process involving Bain Capital, EQT, and TPG reflects strong institutional appetite for consumer health assets with established distribution networks and recognizable brands. All three PE firms bring relevant sector expertise and capital capacity for a transaction at this valuation level. The advancement to non-binding bids signals the sale process is progressing toward binding proposals and deal closure, typically expected within the next two to four months in mid-market transactions of this magnitude.
The transaction is expected to value Vitabiotics at approximately $1.2 billion. The company operates as a leading player in the global vitamins and dietary supplements market, with established brand recognition across multiple product lines. Its primary offerings include Wellman and Wellwoman supplement brands, alongside Hairfollic, a hair health product. The company also maintains a significant presence in the Indian market through Meyer Organics, its domestic subsidiary, expanding its geographic footprint beyond its UK headquarters.
Vitabiotics was founded in 1971 by Kartar Lalwani and remains controlled by the Lalwani family. The company is currently led by Chief Executive Officer Tej Lalwani, the founder's son, who oversees day-to-day operations. The Lalwani family's involvement as controlling shareholders suggests they remain central to the transaction—whether as sellers, partial roll-over equity holders, or both.
The competitive bidding process involving Bain Capital, EQT, and TPG reflects strong institutional appetite for consumer health assets with established distribution networks and recognizable brands. All three PE firms bring relevant sector expertise and capital capacity for a transaction at this valuation level. The advancement to non-binding bids signals the sale process is progressing toward binding proposals and deal closure, typically expected within the next two to four months in mid-market transactions of this magnitude.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.